Atle Fund Management AB Buys 4,674 Shares of Celcuity, Inc. $CELC

Atle Fund Management AB raised its stake in Celcuity, Inc. (NASDAQ:CELC) by 12.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 41,831 shares of the company’s stock after acquiring an additional 4,674 shares during the period. Celcuity accounts for about 1.3% of Atle Fund Management AB’s holdings, making the stock its 29th biggest holding. Atle Fund Management AB’s holdings in Celcuity were worth $4,172,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity in the third quarter valued at approximately $27,000. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Celcuity in the fourth quarter valued at approximately $99,000. Institutional investors own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CELC. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Monday, April 20th. Needham & Company LLC restated a “buy” rating and set a $157.00 target price on shares of Celcuity in a report on Friday, May 15th. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a report on Monday, May 4th. HC Wainwright lifted their price objective on shares of Celcuity from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Craig Hallum reaffirmed a “buy” rating and set a $189.00 price objective on shares of Celcuity in a research report on Monday, May 4th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.30.

Insider Buying and Selling

In related news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 over the last 90 days. Company insiders own 13.33% of the company’s stock.

Celcuity Trading Down 0.8%

Shares of Celcuity stock opened at $131.09 on Wednesday. The firm has a 50-day moving average of $119.52 and a 200-day moving average of $107.75. The stock has a market cap of $6.39 billion, a PE ratio of -33.61 and a beta of 0.09. Celcuity, Inc. has a 52-week low of $10.26 and a 52-week high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, sell-side analysts forecast that Celcuity, Inc. will post -3.87 EPS for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.